Nanosonics Limited · ASX:NAN
Nanosonics — FY2015 Earnings Presentation
19 slides from Nanosonics's earnings presentation, Aug 21, 2015
Slide 1: Leader in Infection Control Solutions: 2015 Full Year Results
For personal use only Leader in Infection Control Solutions 2015 Full Year Results Investor Presentation
Slide 2: Disclaimer
For personal use only Disclaimer This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, fina
Slide 3: Corporate Mission
For personal use only Corporate Mission We improve the safety of patients, clinics, their staff and the environment by transforming the way infection prevention practices are understood and conducted, and introducing innovative technologies that deliver improved standards of care. Johns Hopkins Phot
Slide 4: Company Overview
For personal use only Company Overview • Proprietary automated technology for low temperature, high level disinfection • First product, trophon® EPR, for high level disinfection of ultrasound probes • Approved for sale in most major markets including: US/Canada, ANZ, Europe, Singapore, HK, South Kor
Slide 5: Company Overview: Key Corporate Data
For personal use only Company Overview Key Corporate Data (as at 30 June 2015) $2.00 $1.90 Share price $1.70 $1.80 NAN ($) $1.70 Shares on issue 282.91 million $1.60 $1.50 Market capitalisation $481 million $1.40 $1.30 Liquidity (30 day avg) 527,000 shares $1.20 $1.10 Cash $45.7 million $1.00 $0.90
Slide 6: 2015 Highlights
2015 Highlights For personal use only • Ongoing strong growth in the installed base - now in excess of 5,000 in US • North American direct sales operations now established • European distribution expanded into five new countries with partner Miele Professional • Formal research conducted in Japan in
Slide 7: 2015 Financial Results
For personal use only 2015 Financial Results • Sales up 3.4% to $22.2 million – In line with plan as North American direct sales FY15 FY14 operations established $ million H1 H2 FY15 H1 H2 FY14 • Gross Profit up $1.4 million to $15.3 million Sales Revenue 14.3 7.9 22.2 9.7 11.8 21.5 • GP% up to 69%
Slide 8: US sales growth in line with plan
US sales growth in line with plan For personal use only Sales $17.7 $17.7 • FY15 sales of $17.7 million $ million consistent with pcp due to H2 H1 $13.2 $5.6 transformation of business model $9.7 in H2 $10.2 • trophon EPR now represented in $10.1 $6.5 $12.1 44 of the top 50 hospitals and in $8.0 mor
Slide 9: US direct sales operation
For personal use only US direct sales operation • Direct sales operation covering all US territories established • 18 highly qualified sales professionals trained and focussed on building sales pipeline • Warehousing, order fulfilment and direct service fully operational • Establishing Nanosonics as
Slide 10: ANZ setting the benchmark for standard of care
ANZ setting the benchmark for standard of For personal use only care • Sales of $2.3 million Sales $2.3 $2.3 • Installed base grew 13% and now $ million approaching 1,000 units $1.7 $1.5 • trophon EPR becoming standard of care in ANZ • Market penetration ~ 60% FY12 FY13 FY14 FY15 10
Slide 11: Europe/ROW sales growing strongly
Europe/ROW sales growing strongly For personal use only • FY15 sales of $2.3 million up 45% on pcp Sales • UK primary driver of sales in the $2.3 $ million period with installed base now ~250 units across 40 sites $1.6 • New Welsh guidelines supporting trophon and guidelines in England and Scotland
Slide 12: New global headquarters support strategic growth objectives
New global headquarters support strategic For personal use only growth objectives 12
Slide 13: Clinical research program demonstrates trophon EPR superior efficacy
Clinical research program demonstrates For personal use only trophon EPR superior efficacy • Expanded efficacy testing with independent laboratories against pathogens such as HIV and Chlamydia • Study by University Hospital Munster showed 3 x higher risk of cross contamination with manual wipe metho
Slide 14: trophon EPR first and only system to kill HPV
For personal use only trophon EPR first and only system to kill HPV • 2014 study showed disinfectants commonly used on ultrasound probes not effective against human papillomavirus (HPV) • Worked with researchers at Penn State College of Medicine and Brigham Young University • Key highlight was annou
Slide 15: R&D investment
For personal use only R&D investment • More than $5 million invested in R&D activities across mechanical, electrical and software engineering, microbiology and chemistry • Active programs underway on – Next generation trophon – New disinfectant chemistries – New decontamination devices 15
Slide 16: Compatible with more than ultrasound transducer models
Compatible with more than 900 ultrasound For personal use only transducer models • Expanded number of ultrasound probes approved with trophon from 600 to 900 • Covers all world’s leading manufacturers • Includes both intracavitary and surface probes 16
Slide 17: Focusing on core corporate objectives
For personal use only Focusing on 5 core corporate objectives Establish our offerings as new standards of care globally and Customer Experience provide customers a convenient, seamless and consistent experience with both product and brand Create and bring to market a portfolio of innovative and qual
Slide 18: Business outlook – Positioned for continued growth
Business outlook – Positioned for continued For personal use only growth • Direct North American sales operations in place • Growing installed base • Expanding territories in Europe and Asia Pacific • Market fundamentals for standard of care strengthening with highly relevant clinical data • Ongoing
Slide 19: For personal use only
a) © AjUO esn jeuosied JOS